Abstract:Background: The current research aimed to create and analyze a new long-acting Brexpiprazole (BRX) injectable for successful anti-psychotic drug therapy in order to decrease dosage frequency and increase patient compliance. Systems for drug transport to particular body sites or regulating release rates with accuracy are known as drug delivery systems (DDS). By affixing the drug to a carrier particle like liposomes, nanoparticles, microspheres, etc., which modifies the drug's absorption and release properties, using carrier technology, drugs may be delivered in an intelligent manner. Methods: Utilizing Resomer RG 502 H and RESOMER® RG 752 H extended-release Polymer, Using a quasi-emulsion solvent diffusion, microspheres were made, and emulsification and solvent evaporation process. Results: The produced microspheres were assessed for stability tests, in vitro drug release, flow characteristics, and drug entrapment efficiency. FTIR experiments were used to establish how well the drug excipients worked together. The acarbose microspheres that were created had an 89.9 to 96.1 percent drug entrapment efficiency. The impact of factors like polymer content on medication release was studied. The Stability study of the formulation was carried out under different conditions, and data were established. Comparative pharmacokinetic studies between marketed oral formulation and Brexpirazole microsphere test formulations in Wistar/SD Rats were carried out and concluded. Conclusion: Brexpiprazole (BRX) novel long-acting injectable formulation, could be used effectively for the treatment of mentally challenged anti-psychotic patients worldwide. result: The acarbose microspheres that were created had an 89.9 to 96.1 percent drug entrapment efficiency. The impact of factors like polymer content on medication release was studied. The Stability study of the formulation was carried out under different conditions and data were established. Comparative pharmacokinetic studies between marketed oral formulation and Brexpirazole microsphere test formulations in Wistar/SD Rats were carried out and concluded. conclusion: Based on Literature data and drug excipients compatibility polymers were selected for manufacturing of extended release brexpiprazole microsphere Formulation. Preliminary formulation trial batches were taken with different polymers and studied for Drug Entrapment Efficiency and In Vitro release of drugs. Drug entrapment efficiency data of all the formulations are found satisfactory. In vitro, release results are compared with each formulation and based on the data, trial batch B1 with RESOMER® RG 502 H Poly(D,L-lactide-co-glycolide) 50:50 polymer and trial batch B2 with RESOMER® RG 752 H Poly(D,L-lactide-co-glycolide) 75:25 polymer have satisfactory results. So based on the study RESOMER® RG 502 H Poly(D,L-lactide-co-glycolide) 50:50 and RESOMER® RG 752 H Poly(D,L-lactide-co-glycolide) 75:25 were selected for Polymer Concentration and Formulation optimization study. The formulation is kept in the stability at different conditions and based on the data, the formulation is robust and all the derived values are found satisfactory. The comparative pharmacokinetic study was performed using oral marketed formulation and Brexpiprazole microsphere formulation. Based on the data we can conclude that long-acting depot formulations for administration of Brexpiprazol microsphere may offer no first-pass effect, increased bioavailability, fewer fluctuations in blood concentration and time, less dosing frequency, less no gastrointestinal intolerance, noninvasiveness.

NOVEL FORMULATION DESIGN AND IN-VITRO EVALUATION OF EXTENDED RELEASE PELLETS BY COMPLEXATION TECHNIQUE

Delayed Sustained Drug Release from Electrostatic Powder Coated Tablets with Ultrafine Polymer Blends

Formulation and Evaluation of Extended Release Oral Suspension of Metformin Hydrochloride

Development and evaluation of diltiazem hydrochloride controlled-release pellets by fluid bed coating process

Formulation and Evaluation of Delayed Release Pellets of Ivabradine Hydrochloride

Effect of lipid and cellulose based matrix former on the release of highly soluble drug from extruded/spheronized, sintered and compacted pellets

Formulation Development and Evaluation of Divalproex Sodium Extended-release Tablets

STATISTICAL DESIGN OF EXPERIMENT-BASED FORMULATION DEVELOPMENT AND OPTIMIZATION OF FLOATING MATRIX TABLET OF ANTI-EMETIC DRUG

Formulation and Evaluation of Extended Release Floating Matrix Tablet of Eperisone Hydrochloride by Direct Compression Method

Optimization and Characterization of Novel Sustained Release Supermicro-Pellet Based Dry Suspensions That Load Dexibuprofen

Design, formulation, and evaluation of delayed release oral dosage form of proton pump inhibitor

Preparation of Nitrendipine Sustained-Release Pellet Using Extrusion-Spheronization Technology and Investigations of Its Formulation

FORMULATION DEVELOPMENT AND OPTIMISATION OF FAST DISSOLVING BUCCAL FILMS LOADED GLIMEPIRIDE SOLID DISPERSION WITH ENHANCED DISSOLUTION PROFILE USING CENTRAL COMPOSITE DESIGN

Formulation development and in vitro Evaluation of sustained release matrix tablets of Cefpodoxime proxetil

Formulation, Design, Optimization, and Characterization of Novel Long-acting Injectable Dosage Form of Anti-Psychotic Drug

STUDY OF INFLUENCE OF FORMULATION AND PROCESS VARIABLES ON ENTRAPMENT EFFICIENCY AND PARTICLE SIZE OF FLOATING MICRO BALLOONS OF DIPYRIDAMOLE BY DOE

Preparation and Quality Evaluation of a Novel Multi-Unit Dosage Form by Compaction of Enteric Pellets

In- vitro Design and Formulation of Levitiracetam Extended Release Tablets

Production of antihyerglycemic and antihypertensive drug loaded sustained release nanoparticles using spray drying technique: Optimization by Placket Burman Design

FORMULATION DEVELOPMENT AND OPTIMIZATION OF EMPAGLIFLOZIN FILM COATED TABLET USING QUALITY-BY-DESIGN APPROACH

Single-Step Extrusion Process for Formulation Development of Self-Emulsifying Granules for Oral Delivery of a BCS Class IV Drug.